Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript
Schrodinger NASDAQ: SDGR said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist.
Schrodinger, Inc. (SDGR) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.59 per share a year ago.
Schrödinger is challenging the incumbent drug-trial method—physics-simulated molecular design that cuts the cost, time, and animal testing of building and screening thousands of candidates. The current EV is roughly accounted for by the software leg alone - the royalties business and the disruption TAM are barely priced in, if at all. Three drivers - a regulatory push away from animal testing, AI-led consumption growth, and Bunsen - open up asymmetric upside that is not required for the base case.
Schrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Schrödinger, Inc. (SDGR) Q1 2026 Earnings Call Transcript
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.82 per share a year ago.
On April 22, 2026, Schrodinger Inc (SDGR) shares fell 4.1% today, bringing the current price to $12.35. The stock has experienced a 52-week range between $10.95
Schrödinger, Inc. (SDGR) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Schrödinger, Inc. (SDGR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Schrödinger, Inc. (SDGR) Q4 2025 Earnings Call Transcript
The consensus price target hints at a 46.2% upside potential for Schrodinger (SDGR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.